Seoul BioHub announced on the 26th that Daewon Pharmaceutical and biotech startup Atomatrix have signed a research service agreement for AI modeling for new drug development through the "2025 Seoul BioHub-Daewon Pharmaceutical Open Innovation Program." This agreement demonstrates the program's operational performance, demonstrating how collaborative projects identified through the Open Innovation Program have led to specific research projects.
Atomatrix possesses CANDDIE, an integrated drug design platform based on AI and molecular dynamics (MD). Its core analysis engines include "Allopiper," a module for predicting membrane protein pharmacological signaling characteristics, and "BARon," a module for predicting protein-drug binding stability. Daewon Pharmaceutical plans to use this platform to precisely analyze the mechanism of action and selectivity of candidate compounds and enhance the quality of its new drug pipeline.
Through its Open Innovation Program, Seoul BioHub systematically matches the technological needs of promising biotech startups with those of large and mid-sized pharmaceutical companies, supporting them through technology review, collaborative discussions, and follow-up collaborations. This research service contract is significant in that it marks a tangible outcome of the program, marking a milestone in the process from discussion to actual research.
A Daewon Pharmaceutical official stated, "This research project is a step-by-step collaboration to examine the potential application of external innovative technologies. We plan to carefully review the direction of our new drug research based on the results of our AI-based modeling." An Atomatrix representative stated, "Collaborating with a major pharmaceutical company is a crucial opportunity to validate our platform's effectiveness and expand our business."
Seoul Bio Hub plans to recruit companies to participate in the 'Seoul Bio Hub-Daewon Pharmaceutical Open Innovation Program' scheduled to begin in April 2026, and will pursue expansion of the open innovation ecosystem in connection with the bio open innovation chain in the future.
- See more related articles
You must be logged in to post a comment.